TAXIS Pharmaceuticals Moves to High-Tech Business Incubator Developer of Novel Antibiotics Accepted at the Tech Centre of New Jersey

NEW BRUNSWICK, NJ – September 22, 2010 – TAXIS Pharmaceuticals, a development stage drug discovery company working on a novel class of antibiotics aimed at multidrugresistant infections, has moved into the Tech Centre of New Jersey, effective September 1, 2010.

“We’re honored to join the many innovative New Jersey companies at the Tech Centre,”said Greg Mario, CEO of TAXIS. “The state-of-the-art facilities there will prove invaluable to our efforts to develop new ways to fight the dangerous drug-resistant bacterial infections that are an alarming and growing health threat worldwide.”

A project of the New Jersey Economic Development Authority, the Tech Centre of New Jersey will give TAXIS access to advanced wet and dry laboratory space in its Commercialization Center for Innovative Technologies (CCIT) facility. As a CCIT tenant, TAXIS will also enjoy a wide variety of support services, including scientific, technical, and business advice, as well as the chance to partner with the state’s major healthcare corporations through the incubator’s Strategic Partner Advantage Network.

NJEDA CEO Caren Franzini noted that TAXIS is a welcome addition to the impressive roster of companies at the Tech Centre. “The Technology Centre of New Jersey has evolved into a world-class facility that has helped to enhance the State’s entrepreneurial environment by providing emerging biotech companies with the resources they need to thrive,” Franzini said. “TAXIS has already made its mark in the industry and we look forward to another New Jersey success story.”

TAXIS Pharmaceuticals, a development-stage drug discovery company, has identified and patented five new classes of proprietary antibiotic agents that exploit a novel mechanism of action distinct from any other antibiotic in clinical use today. These agents potentially represent the first transformational innovation in antibiotic technology in more than three decades. If successful, the TAXIS compounds will revolutionize the treatment of multidrug resistant bacterial infections such as methicillin-resistant Stapylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococci (VRE),Clostridium difficile (C-diff), Pseudomonas aeruginosa, and Acinetobacter baumannii; collectively, a therapeutic category with annual revenues in excess of $25B worldwide.

Founded in 2009 and based in New Brunswick, NJ, privately-held TAXIS has several lead compounds in pre-clinical stages of development, with its first compound projected to enter clinical trials in 2012.


<a href=””></a>